News >

PEGPH20 Could Alter Frontline Treatment in Pancreatic Cancer

Angelica Welch
Published: Wednesday, Sep 27, 2017

Robert R. McWilliams, MD

Robert R. McWilliams, MD
Optimizing frontline therapy for patients with pancreatic cancer is an ongoing focal point in the field, according to Robert R. McWilliams, MD.

With the statistically significant results coming out of the HALO-202 trial, and the impending findings of the phase III HALO-301 trial, PEGPH20 has the potential to be added to the standard first-line therapy for patients with mPDA who are HA-high, experts explained.


  1. Hendifar A, Bullock A, Seery T, et al. Tumor hyaluronan may predict benefit from PEGPH20 when added to nab paclitaxel/gemcitabine in patients with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDA). [ESMO WGI Abstract O-028]. Ann Oncol. 2017;28(suppl_3):iii137-iii149. doi: 10.1093/annonc/mdx262.
  2. Hingorani S, Bullock A, Seery T, et al. Randomized phase II study of PEGPH20 plus nab-paclitaxel/gemcitabine (PAG) vs AG in patients (Pts) with untreated, metastatic pancreatic ductal adenocarcinoma (mPDA). J Clin Oncol. 2017;35(15):4008. doi: 10.1200/JCO.2017.35.15_suppl.4008.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication